- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GRI BIO Aktie jetzt für 0€ handeln | |||||
| Do | GRI Bio reports Q1 results | 1 | Seeking Alpha | ||
| Do | GRI Bio reports phase 2a data for IPF drug candidate GRI-0621 | 2 | Investing.com | ||
| Do | GRI Bio, Inc.: GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline | 177 | GlobeNewswire (Europe) | Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm - suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities... ► Artikel lesen | |
| Do | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | GRI Bio, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.04. | GRI Bio, Inc.: GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions | 1 | GlobeNewswire (USA) | ||
| 17.02. | GRI Bio, Inc.: GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment | 1 | GlobeNewswire (USA) | ||
| 04.02. | GRI Bio reports FY results | 1 | Seeking Alpha | ||
| 04.02. | GRI Bio reports $8.2 million cash position, extends runway into Q1 2027 | 2 | Investing.com | ||
| 04.02. | GRI Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.02. | GRI Bio, Inc.: GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights | 241 | GlobeNewswire (Europe) | Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations... ► Artikel lesen | |
| 30.01. | GRI Bio, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 28.01. | GRI Bio reports positive gene expression data for IPF drug candidate | 2 | Investing.com | ||
| 28.01. | GRI Bio, Inc.: GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF | 235 | GlobeNewswire (Europe) | Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio"... ► Artikel lesen | |
| 28.01. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.01. | GRI Bio, Inc.: GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures | 2 | GlobeNewswire (USA) | ||
| 22.01. | GRI Bio Announces Reverse Stock Split To Regain Minimum Bid Price Nasdaq Compliance | - | RTTNews | ||
| 21.01. | GRI Bio announces 1-for-28 reverse share split | 1 | Seeking Alpha | ||
| 21.01. | GRI Bio: Aktienzusammenlegung im Verhältnis 1:28 soll Verbleib an der Nasdaq sichern | 6 | Investing.com Deutsch | ||
| 21.01. | GRI Bio announces 1-for-28 reverse stock split to regain Nasdaq compliance | 1 | Investing.com |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,40 | -2,98 % | BioNTech-Krise vs. Emyria-Durchbruch? Warum Daten jetzt die Forschung schlagen | ||
| EVOTEC | 4,618 | -1,74 % | KURSRUTSCH bei Nel ASA und Evotec! KURSCHANCE bei HPQ Silicon! | Steht die Aktie von HPQ Silicon vor einer Neubewertung? Dafür gibt es jedenfalls gute Gründe. Die Hochleistungsbatterien haben erneut überzeugt. Damit könnte für Anwendungen in Drohnen, Verteidigung... ► Artikel lesen | |
| AMGEN | 282,15 | +0,46 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,400 | +1,15 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,309 | +3,00 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Grant of Restricted Stock Units | Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,405 | +1,00 % | Exosomen als Hoffnungsträger: Neuer Ansatz in der Glaukomtherapie | ||
| ABIVAX | 100,00 | +0,86 % | EQS-News: ABIVAX: Abivax Announces Results of its May 11, 2026 Annual General Meeting | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11.05.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| IBIO | 1,274 | +0,39 % | iBio, Inc. - 10-Q, Quarterly Report | ||
| ARROWHEAD PHARMACEUTICALS | 65,68 | -0,45 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events | Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
BofA Securities 2026 Healthcare Conference May 12-14, 2026
Type:... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,580 | +10,49 % | Voyager Therapeutics, Inc.: Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 | - VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON... ► Artikel lesen | |
| CYBIN | 4,035 | +0,50 % | Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs | Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO... ► Artikel lesen | |
| CAPRICOR | 24,850 | +0,28 % | CAPRICOR THERAPEUTICS, INC. - 10-Q, Quarterly Report | ||
| OPGEN | 1,568 | 0,00 % | CapForce Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| APELLIS PHARMACEUTICALS | 34,880 | 0,00 % | XFRA 1JK: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAPELLIS PHARMACT.DL-... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,208 | 0,00 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen |
Das Unternehmen GRI BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,010 (+0,49 %) liegt der Kurs bei 2,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GRI BIO INC finden Sie auf Wallstreet Online.